Join to access to all OVN content. Join for Free

Results for 'Epoetin'

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Epoetin, Biosimilars, Interchangeable, Substitution, Guidelines

Biosimilars are biologic drug products similar to reference drugs in various attributes, including safety and efficacy. Biosimilar epoetin was approved by the FDA in 2018 after previous non-approval letters in 2015 and 2017 despite positive reviews by the FDA's Oncologic Drugs Advisory Committee …

Mar 12th • 7 mins read

Addressing oncologists' gaps in the use of biosimilar products
OVN Avatar Chad Williamson, MBA, MS Leanne Berger, BS, Thomas P. Sullivan, BS SHOW
Addressing oncologists' gaps in the use of biosimilar products

biosimilar products, FDA, biosimilars, COA

The study highlights significant gaps in knowledge, competence, and confidence among oncologists regarding biosimilars. Educational interventions notably improved clinicians' understanding of the biosimilar approval process and familiarity with approved products. Post-education familiarity with the …

Jun 19th • 5 mins read

Related Topics

Loading...